Antibodies for bioanalysis and drug monitoring of nivolumab

Develop highly selective and sensitive PK and ADA assays for the immune checkpoint inhibitor drug nivolumab (Opdivo) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to nivolumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Nivolumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Nivolumab Inhibitory

Type 1

HCA299

AbD30255

Fab-FH1

0.5

PK bridging ELISA

Order HCA299

HCA300

AbD30255_hIgG1

hIgG1

0.5

ADA control

Order HCA300

HCA301
HCA301P

AbD30258_hIgG1

hIgG1

HRP

2

PK bridging ELISA

ADA control

Order HCA301
Order HCA301P

HCA302

AbD30260_hIgG1

hIgG1

23

ADA control

Order HCA302

HCA303

AbD30264_hIgG1

hIgG1

14

ADA control

Order HCA303

* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags


Anti-Nivolumab Inhibitory Antibodies (Type 1)

Type 1 anti-nivolumab antibodies inhibit the binding of the drug nivolumab to its target, programmed cell death 1 (PD-1). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in high, medium and lower affinities, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Nivolumab PK bridging ELISA using antibodies HCA299 and HCA301P.

Fig. 1. Nivolumab PK bridging ELISA using antibodies HCA299 and HCA301P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


ADA Bridging ELISA


Fig. 2. Nivolumab ADA bridging ELISA using antibody HCA300, HCA301, HCA302 or HCA303.

Fig. 2. Nivolumab ADA bridging ELISA using antibody HCA300, HCA301, HCA302 or HCA303.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.